Publications 2021


  1. Bacon, JVW, Müller, DC, Ritch, E, Annala, M, Dugas, SG, Herberts, C et al.. Somatic Features of Response and Relapse in Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin Immunotherapy. Eur Urol Oncol. 2021; :. doi: 10.1016/j.euo.2021.11.002. PubMed PMID:34895867 .
  2. Taavitsainen, S, Engedal, N, Cao, S, Handle, F, Erickson, A, Prekovic, S et al.. Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse. Nat Commun. 2021;12 (1):5307. doi: 10.1038/s41467-021-25624-1. PubMed PMID:34489465 PubMed Central PMC8421417.
  3. Ketola, K, Kaljunen, H, Taavitsainen, S, Kaarijärvi, R, Järvelä, E, Rodríguez-Martín, B et al.. Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity. Cancer Res. 2021;81 (19):4901-4909. doi: 10.1158/0008-5472.CAN-21-0371. PubMed PMID:34348967 .
  4. Jasu, J, Tolonen, T, Antonarakis, ES, Beltran, H, Halabi, S, Eisenberger, MA et al.. Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. Eur Urol Open Sci. 2021;30 :47-62. doi: 10.1016/j.euros.2021.05.011. PubMed PMID:34337548 PubMed Central PMC8317817.
  5. Kukkonen, K, Taavitsainen, S, Huhtala, L, Uusi-Makela, J, Granberg, KJ, Nykter, M et al.. Chromatin and Epigenetic Dysregulation of Prostate Cancer Development, Progression, and Therapeutic Response. Cancers (Basel). 2021;13 (13):. doi: 10.3390/cancers13133325. PubMed PMID:34283056 PubMed Central PMC8268970.
  6. Jacome Sanz, D, Saralahti, AK, Pekkarinen, M, Kesseli, J, Nykter, M, Rämet, M et al.. Proprotein convertase subtilisin/kexin type 9 regulates the production of acute-phase reactants from the liver. Liver Int. 2021;41 (10):2511-2522. doi: 10.1111/liv.14993. PubMed PMID:34174143 .
  7. Annala, M, Taavitsainen, S, Khalaf, DJ, Vandekerkhove, G, Beja, K, Sipola, J et al.. Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition. Clin Cancer Res. 2021;27 (16):4610-4623. doi: 10.1158/1078-0432.CCR-21-1625. PubMed PMID:34083234 .
  8. Filppu, P, Tanjore Ramanathan, J, Granberg, KJ, Gucciardo, E, Haapasalo, H, Lehti, K et al.. CD109-GP130 interaction drives glioblastoma stem cell plasticity and chemoresistance through STAT3 activity. JCI Insight. 2021;6 (9):. doi: 10.1172/jci.insight.141486. PubMed PMID:33986188 PubMed Central PMC8262342.
  9. Rajamäki, K, Taira, A, Katainen, R, Välimäki, N, Kuosmanen, A, Plaketti, RM et al.. Genetic and Epigenetic Characteristics of Inflammatory Bowel Disease-Associated Colorectal Cancer. Gastroenterology. 2021;161 (2):592-607. doi: 10.1053/j.gastro.2021.04.042. PubMed PMID:33930428 .
  10. Cangiano, M, Grudniewska, M, Salji, MJ, Nykter, M, Jenster, G, Urbanucci, A et al.. Gene Regulation Network Analysis on Human Prostate Orthografts Highlights a Potential Role for the JMJD6 Regulon in Clinical Prostate Cancer. Cancers (Basel). 2021;13 (9):. doi: 10.3390/cancers13092094. PubMed PMID:33925994 PubMed Central PMC8123677.
  11. Annala, M, Fu, S, Bacon, JVW, Sipola, J, Iqbal, N, Ferrario, C et al.. Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. Ann Oncol. 2021;32 (7):896-905. doi: 10.1016/j.annonc.2021.03.205. PubMed PMID:33836265 .
  12. Cerqueira, JXM, Saavalainen, P, Kurppa, K, Laurikka, P, Huhtala, H, Nykter, M et al.. Independent and cumulative coeliac disease-susceptibility loci are associated with distinct disease phenotypes. J Hum Genet. 2021;66 (6):613-623. doi: 10.1038/s10038-020-00888-5. PubMed PMID:33446885 PubMed Central PMC8144013.
  13. Vandekerkhove, G, Lavoie, JM, Annala, M, Murtha, AJ, Sundahl, N, Walz, S et al.. Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nat Commun. 2021;12 (1):184. doi: 10.1038/s41467-020-20493-6. PubMed PMID:33420073 PubMed Central PMC7794518.
  14. Warner, E, Herberts, C, Fu, S, Yip, S, Wong, A, Wang, G et al.. BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression. Clin Cancer Res. 2021;27 (6):1650-1662. doi: 10.1158/1078-0432.CCR-20-3708. PubMed PMID:33414135 .

Search PubMed